Suppr超能文献

5-羟色胺及几种类似物对人体血小板的相对活性及摄取情况

Relative activities on and uptake by human blood platelets of 5-hydroxytryptamine and several analogues.

作者信息

Born G V, Juengjaroen K, Michal F

出版信息

Br J Pharmacol. 1972 Jan;44(1):117-39. doi: 10.1111/j.1476-5381.1972.tb07244.x.

Abstract
  1. The specificity of platelet receptor sites for 5-HT uptake and for the rapid morphological change and aggregation was investigated with 5-hydroxy-tryptamine (5-HT) and seventeen analogues as well as with some antagonists of 5-HT.2. The analogues, with the exception of 5-hydroxy-N'N'-dibutyltryptamine, caused the rapid morphological change in platelets. In concentrations below those needed to produce the agonistic action (viz. 0.05-2.0 muM), these analogues themselves inhibited competitively the shape change caused by 5-HT.3. The velocity of change in shape caused by 5-HT was reduced in low Na media.4. Ten analogues produced platelet aggregation; three of these, viz. 5-methoxy-alpha-methyltryptamine, 5-hydroxy-alpha-methyltryptamine and 5-hydroxy-N'N'-diisopropyltryptamine), were approximately equipotent with 5-HT. Six analogues did not induce platelet aggregation.5. All the analogues which prevented the initial change in shape of platelets caused by 5-HT also inhibited its aggregating effect, apparently competitively with low K(i) values (0.02-1.6 muM).6. As with the inhibition of shape change, the inhibition of aggregation shows relatively low structural specificity of the receptor site.7. Methysergide was a potent inhibitor of shape change and aggregation (K(i) approximately 0.03 muM); imipramine was much less inhibitory (K(i) approximately 5-10 muM).8. Only one analogue (5-hydroxy-alpha-methyltryptamine) was taken up like 5-HT by platelets. All the other analogues inhibited the uptake of 5-HT by platelets (K(i)=0.2-2.7 muM).9. Methysergide was a weak inhibitor of 5-HT uptake (K(i) approximately 125 muM) whereas imipramine was very effective (K(i) approximately 0.3 muM).10. Our results show that the initial change in shape of platelets is required for and precedes aggregation. The structural specificity of the platelet receptor concerned with shape change and aggregation caused by 5-HT appears low whereas the uptake mechanism is a highly specific one. The uptake probably proceeds through more than one step, the relationship between the steps is not yet clear.
摘要
  1. 用5-羟色胺(5-HT)及其17种类似物以及一些5-HT拮抗剂研究了血小板受体部位对5-HT摄取、快速形态变化和聚集的特异性。

  2. 除5-羟基-N'N'-二丁基色胺外,这些类似物均能引起血小板的快速形态变化。在低于产生激动作用所需的浓度(即0.05 - 2.0μM)下,这些类似物自身竞争性抑制5-HT引起的形状变化。

  3. 在低钠培养基中,5-HT引起的形状变化速度降低。

  4. 10种类似物可引起血小板聚集;其中3种,即5-甲氧基-α-甲基色胺、5-羟基-α-甲基色胺和5-羟基-N'N'-二异丙基色胺,与5-HT的效力大致相当。6种类似物不诱导血小板聚集。

  5. 所有阻止5-HT引起的血小板初始形状变化的类似物也抑制其聚集作用,显然是通过低K(i)值(0.02 - 1.6μM)竞争性抑制。

  6. 与形状变化的抑制一样,聚集的抑制显示受体部位的结构特异性相对较低。

  7. 美西麦角是形状变化和聚集的有效抑制剂(K(i)约为0.03μM);丙咪嗪的抑制作用则小得多(K(i)约为5 - 10μM)。

  8. 只有一种类似物(5-羟基-α-甲基色胺)像5-HT一样被血小板摄取。所有其他类似物均抑制血小板对5-HT的摄取(K(i)=0.2 - 2.7μM)。

  9. 美西麦角是5-HT摄取的弱抑制剂(K(i)约为125μM),而丙咪嗪非常有效(K(i)约为0.3μM)。

  10. 我们的结果表明,血小板的初始形状变化是聚集所必需的且先于聚集。与5-HT引起的形状变化和聚集相关的血小板受体的结构特异性似乎较低,而摄取机制是高度特异性的。摄取可能通过多个步骤进行,各步骤之间的关系尚不清楚。

相似文献

引用本文的文献

本文引用的文献

1
Source of 'serotonin' in serum.血清中“血清素”的来源。
Nature. 1951 Sep 1;168(4270):385. doi: 10.1038/168385b0.
4
6
PLATELET CLUMPING IN VITRO.体外血小板聚集
Br J Haematol. 1964 Jan;10:78-93. doi: 10.1111/j.1365-2141.1964.tb00681.x.
10
The uptake of 5-hydroxytryptamine by blood platelets in the cold.低温下血小板对5-羟色胺的摄取。
J Physiol. 1959 Jun 23;147(1):153-61. doi: 10.1113/jphysiol.1959.sp006230.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验